Journal de pharmacocinétique et thérapeutique expérimentale

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Quantification of Rosuvastatin and its Metabolites through HPLC-Mass Spectrometry for Pharmacokinetic Analysis

Havid Vilava

The pharmacokinetic analysis, the accurate quantification of drug compounds and their metabolites is crucial to understanding their behavior within the body. This study presents a comprehensive investigation into the pharmacokinetics of rosuvastatin and its metabolites utilizing a robust analytical approach combining High- Performance Liquid Chromatography (HPLC) with Mass Spectrometry (MS). The developed HPLC-MS method demonstrates exceptional sensitivity and selectivity, allowing for the simultaneous quantification of rosuvastatin and its metabolites in complex biological matrices. The method validation showcases its precision, accuracy, linearity, and robustness, enabling reliable measurements of concentrations over various time points. A pharmacokinetic study was conducted following the administration of rosuvastatin in a cohort of subjects. Blood samples were collected at predetermined intervals, processed, and analyzed using the established HPLC-MS method. The resulting concentration-time profiles of rosuvastatin and its metabolites provided insights into absorption, distribution, metabolism, and excretion patterns. The findings elucidate the metabolic pathways of rosuvastatin, shedding light on the formation of metabolites and their subsequent kinetics. The obtained pharmacokinetic parameters contribute to a deeper understanding of the drug's behavior within the human body, potentially guiding dosing regimens and therapeutic strategies. In conclusion, the integration of HPLC with mass spectrometry has proven to be a valuable tool for investigating the pharmacokinetics of rosuvastatin and its metabolites. This analytical approach not only advances our comprehension of drug metabolism and disposition but also holds promise for optimizing treatment approaches in individuals requiring rosuvastatin therapy.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.